The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 09, 2008
Filed:
Nov. 30, 2005
Ponnampalam Gopalakrishnakone, Singapore, SG;
Maung-maung Thwin, Singapore, SG;
Kandiah Jeyaseelan, Melbourne, AU;
Arunmozhiarasi Armugam, Singapore, SG;
Ponnampalam Gopalakrishnakone, Singapore, SG;
Maung-Maung Thwin, Singapore, SG;
Kandiah Jeyaseelan, Melbourne, AU;
Arunmozhiarasi Armugam, Singapore, SG;
National University of Singapore, Singapore, SG;
Abstract
A phospholipase Ainhibitor protein designated 'Phospholipase Inhibitor from Python' (PIP)—formerly designated 'Python Antitoxic Factor' (PAF)—is given by SEQ ID NO:2. The partial amino acid sequence for PIP was initially determined from the native protein purified from the blood serum of a non-venomous snake,. The complete PIP polynucleotide sequence was obtained from a cDNA clone encoding PIP, given by SEQ ID NO:1, along with the full amino acid sequence deduced from it. Also disclosed is a recombinant protein PIP, which shows strong lethal toxin neutralizing activity similar to the native PIP, and has potent anti-inflammatory activity. Both the native and the functionally equivalent recombinant PIP are useful for the prevention or treatment of conditions such as snakebites, insect stings, and inflammatory diseases. Also, phospholipase A(PLA) inhibitory polypeptides designated P-0029, P-0009, and P-0006, the sequences of which are given as SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, respectively, are disclosed. Those polypeptides, and their synthetic chemical analogues and polypeptide variants that inhibit PLAactivity and alleviate inflammation, may also be used in the diagnosis, study, prevention, and treatment of PLA-related human inflammatory diseases.